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Microbiological, Clinical, and Surgical Features
of Fungal Prosthetic Joint Infections:
A Multi-Institutional Experience
By Khalid Azzam, MD, Javad Parvizi, MD, FRCS, Donald Jungkind, PhD, Diplomate (ABMM), Arlen Hanssen, MD,
Thomas Fehring, MD, Bryan Springer, MD, Kevin Bozic, MD, Craig Della Valle, MD, Luis Pulido, MD, and Robert Barrack, MD
Introduction
Periprosthetic joint infection is one of the most dreaded andcomplex complications of total joint arthroplasty. Peri-
prosthetic joint infection is now the major cause of failure
following total knee arthroplasty1 and the third most common
cause of failure following total hip arthroplasty 2. It is estimated
that the prevalence of periprosthetic joint infection may be
on the rise3. A wide variety of pathogens are known to cause
periprosthetic joint infection, with the majority of infections
being caused by gram-positive bacteria, especially staphylococ-
cal species4,5. The treatment of a confirmed periprosthetic joint
infection often includes the need for surgical intervention,
and two-stage exchange arthroplasty is the most common mode
of surgical treatment in North America. Two-stage exchange
arthroplasty relies on removal of all foreign material and in-
sertion of an antibiotic-impregnated cement spacer for the
purpose of delivering high doses of antibiotics locally in the
interval of time between the resection arthroplasty and
subsequent reimplantation.
Periprosthetic infection with fungi, although rare, rep-
resents a diagnostic and therapeutic challenge to which clear
guidelines have not yet been established. It is not known if the
protocol for treatment of a bacterial periprosthetic joint in-
fection can also be applied in the same manner to fungal in-
fections. Patients with fungal periprosthetic joint infection
are believed to be a different type of host with decreased
cellular immunity, mostly due to an underlying cause of im-
munosuppression, such as malignant disease, drug therapies
(antineoplastic agents, corticosteroids, or immunosuppressive
drugs), overuse or inappropriate use of antibiotics, and in-
dwelling catheters (urinary or parenteral hyperalimentation).
Other factors, such as diabetes, tuberculosis, intravenous drug
use, and acquired immunosuppressive disease, are associated with
an increased frequency of mycotic infection6. The lack of reliable
antifungal medications for systemic and, in particular, local de-
livery poses a real challenge in pathogen-directed treatment. The
literature contains few reports of fungal periprosthetic joint in-
fection. In fact, our search of the entire English literature revealed
a total of forty-six patients7-40. The vast majority of those in-
fections were caused by Candida species. Previous case reports
present a wide variety of treatment methods, both surgical and
medical, as well as variable outcomes. Based on the very small
number of patients in each report, it is difficult to draw firm
conclusions regarding the outcome of treatment for this chal-
lenging problem. Further, the surgical treatment varies consid-
erably for these patients, making interpretation of the presented
data difficult and not directly comparable.
The purpose of this multicenter study was therefore to
investigate the issues surrounding this rare condition with re-
spect to patient characteristics and the currently implemented
therapeutic strategies and their effectiveness. In particular, this
study sought to determine the efficacy of two-stage exchange
arthroplasty in the treatment of these complex infections.
Materials and Methods
We performed a review of joint arthroplasty databases insix centers to identify patients who were diagnosed with
a periprosthetic fungal infection. Patients were diagnosed with
fungal periprosthetic joint infection according to a positive
preoperative aspiration culture and/or a positive intraoperative
culture. We collected patient-specific information, including
demographics, body mass index, smoking habits, comorbid-
ities (especially immunity-impairing risk factors such as di-
abetes mellitus, corticosteroid therapy, malignant disease, and
organ transplantation), and prolonged antibiotic treatment.
Medical records were reviewed at each center to identify the
clinical, laboratory, and operative characteristics of patients
with infection as well as the treatment protocols that had been
used. Patients were followed radiographically for at least two
years or until recurrence of the infection. The average period of
follow-up for patients who remained free of infection was
forty-five months (range, twenty-four months to eleven years).
Institutional review board approval was obtained in each
center prior to initiating the study.
Disclosure: The authors did not receive any outside funding or grants in support of their research for or preparation of this work. One or more of the
authors, or a member of his or her immediate family, received, in any one year, payments or other benefits in excess of $10,000 or a commitment or
agreement to provide such benefits from commercial entities (Stryker Orthopaedics, Zimmer, Smith and Nephew, Biomet, and DePuy).
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Results
From 1999 to 2006, a total of thirty-one patients with fungalinfection about a total hip or knee prosthesis were iden-
tified. There were seventeen women and fourteen men with an
average age of sixty-four years (range, thirty-six to eighty-six
years) at the time of diagnosis, and they had an average body
mass index of 29.1 kg/m2 (range, 17 to 48.6 kg/m2). Infection
occurred after knee arthroplasty in seventeen patients and after
hip arthroplasty in fourteen patients. Twenty-seven patients
had one or more underlying systemic illnesses (Fig. 1), in-
cluding cardiac disease in twelve patients, chronic liver disease
in six patients, diabetes mellitus in six patients, rheumatoid
arthritis in five patients, malignant disease in three patients,
and chronic renal failure in two patients. Six patients were
receiving systemic corticosteroid therapy at the time of pre-
sentation. Seven patients received a prolonged course of anti-
biotics prior to the development of the fungal infection. In
four patients, no risk factors of impaired immunity could be
identified. Two of those four patients developed the infection
after multiple (more than five) revision surgeries. Another
patient had a complicated history of multiple gunshot wounds
to the extremity with the infected joint.
The interval from the index surgery to the diagnosis of
infection averaged twenty-five months (range, one month to
twelve years). Fungal periprosthetic infection occurred after
a primary arthroplasty in eleven patients and after a revision
arthroplasty in the remaining twenty patients. All patients
presented with symptoms and signs of chronic infection,
which included chronic pain and swelling. None of the pa-
tients had systemic symptoms including fever. Loosening of
the implant was detected radiographically in seven patients,
with extensive femoral osteolysis detected in one patient. The
average erythrocyte sedimentation rate and C-reactive protein
level were 54 mm/hr (range, 12 to 104 mm/hr) and 17.5 mg/L
(range, 0.6 to 73.9 mg/L), respectively. In eleven patients,
preoperative aspiration and examination of the joint fluid
revealed an average white blood-cell count of 8761 cells/mL
(8.76 · 109/L) (range, 440 to 26,700 cells/mL [0.4 to 26.7 ·
109/L]) with an average neutrophil differential of 76% (range,
19% to 94%).
Candida species was the causative pathogen in the
majority of the patients. Candida albicans was grown in cultures
of specimens from twenty patients; Candida parapsilosis, in
four patients; both fungi in three patients; and Candida glabrata,
in one patient. Non-Candida species were isolated in three
patients and included Aspergillus in one patient, Rhodotorula
minuta in another patient, and Aureobasidium in the third
patient. An intraoperative Gram stain did not reveal organisms
in any of the patients. A coexisting bacterial infection was
detected in five patients; the organisms included coagulase-
negative Staphylococci in three patients, vancomycin-resistant
enterococci in one patient, and Staphylococcus aureus in an-
other patient.
Irrigation and de´bridement was the initial surgical
treatment in seven patients, none of whom had resolution of
the infection. Five of these patients required removal of the
prosthesis to eradicate the infection. Due to the extent of bone
loss, which prohibited further reconstruction, the infection
was suppressed with oral fluconazole in the remaining two
patients. Meanwhile, twenty-four patients were initially man-
Fig. 1
Potential immunity-impairing risk factors in the study population. (Note: the numbers do not equal
the number of patients due to overlap.)
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aged with resection of the components. Thus a total of twenty-
nine patients required resection arthroplasty to control the
infection (Fig. 2). Implants and cement, whenever present,
were removed, and a thorough de´bridement of devitalized
tissues was carried out in all patients. For all patients, a spacer
was inserted that contained the antibiotics tobramycin and
vancomycin; in five patients, the spacer also contained the
antifungal medication amphotericin.
Of the twenty-nine patients who underwent resection
arthroplasty and spacer insertion, delayed reimplantation was
performed in nineteen at an average of seven months (range,
two to fourteen months) after the resection arthroplasty.
Multiple intraoperative cultures were obtained at the time of
reimplantation, and these cultures were negative in all nineteen
patients. Ten of the nineteen patients showed signs of persis-
tent or recurrent infection after reimplantation. Four of these
ten underwent further irrigation and de´bridement; the cul-
tures that were obtained during that procedure did not dem-
onstrate any fungal growth and these patients were free of
infection at the time of the latest follow-up as of the time of
writing. Two of the ten patients underwent above-the-knee
amputation. Of the remaining four of these ten patients, one
patient died due to uncontrolled sepsis that resulted in mul-
tiple organ system failure, another patient was managed on
long-term suppressive antimicrobial therapy, and two patients
refused additional surgery. As a result of uncontrolled in-
fection, reimplantation was never performed in ten of the
twenty-nine patients. Multiple operative de´bridement and
spacer exchange procedures were performed in an attempt to
control the infection. Nevertheless, the final outcome of these
ten patients was above-the-knee amputation in three patients,
knee arthrodesis in three patients, permanent resection ar-
throplasty of the hip in three patients, and hip disarticulation
in one patient (Fig. 2).
Following the initial surgical treatment (resection ar-
throplasty or de´bridement), all thirty-one patients were
managed with six weeks of intravenous antifungal agents.
Fluconazole was used in twenty-three patients, with an initial
dose of 800 mg/day that was gradually tapered to 400 mg/day.
Three patients were treated with caspofungin (50 to 75 mg/
day) in addition to fluconazole. Amphotericin B, 3 mg/kg/day,
was used in five patients. Antifungal susceptibility testing
Fig. 2
A flowchart outlines the surgical treatment of fungal prosthetic joint infection in thirty-
one patients from six different centers between 1999 and 2006.
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TABLE I Reports of Fungal Prosthetic Joint Infections*
No. Study Organism Joint Treatment Outcome Follow-up
1 MacGregor et al.26 (1979) Candida parapsilosis Knee Resection arthroplasty Arthrodesis 1 yr
2,3 Goodman et al.17 (1983) Candida tropicalis Knee Resection arthroplasty Arthrodesis 1 yr
Candida glabrata Hip Resection arthroplasty Resection arthroplasty 1 yr
4 Younkin et al.40 (1984) Candida parapsilosis Hip Resection arthroplasty Resection arthroplasty 2 yr
5 Koch20 (1988) Candida albicans Knee Resection arthroplasty Arthrodesis 21 mo
6 Iskander and Kahn19 (1988) Candida albicans Knee Resection arthroplasty Arthrodesis N/A
7 Levine et al.25 (1988) Candida albicans Knee Resection arthroplasty Arthrodesis 2 yr
8,9 Lambertus et al.21 (1988) Candida tropicalis Hip Resection arthroplasty Resection arthroplasty 2 yr
Candida tropicalis Knee Resection arthroplasty Resection arthroplasty 14 mo
10-13 Darouiche et al.13 (1989) Candida albicans Hip
(2 cases)
Resection arthroplasty Resection arthroplasty 7 mo
Candida albicans Knee Resection arthroplasty Resection arthroplasty 6 wk
Candida tropicalis Hip Resection arthroplasty Resection arthroplasty 3 yr
14,15 Evans and Nelson14 (1990) Candida albicans Hip
(2 cases)
Resection arthroplasty Resection arthroplasty 3.5 yr
16 Paul et al.30 (1992) Candida parapsilosis Knee Resection arthroplasty Arthrodesis 2 yr
17 Austin et al.8 (1992) Aspergillus fumigatus Knee Resection arthroplasty Resection arthroplasty 12 wk
18 Tunkel et al.35 (1993) Candida parapsilosis Knee Antifungal therapy Amputation N/A
19 White and Goetz37 (1995) Candida parapsilosis Knee Resection arthroplasty Resection arthroplasty 2 yr
20-22 Cardinal et al.11 (1996) Candida albicans Hip
(3 cases)
Resection arthroplasty Resection arthroplasty 6 mo
to 1 yr
23 Hennessy18 (1996) Candida parapsilosis Knee Two-stage exchange Infection cleared 2 yr
24 Nayeri et al.29 (1997) Candida glabrata Hip Resection arthroplasty Resection arthroplasty 2 yr
25 Cushing and Fulgenzi12 (1997) Candida parapsilosis Knee Antifungal therapy Infection suppression 1 yr
26 Fukasawa and
Shirakura15 (1997)
Candida parapsilosis Knee De´bridement Infection cleared 2 yr
27 Simonian et al.34 (1997) Candida albicans Knee De´bridement Infection cleared 6 yr
28 Selmon et al.33 (1998) Candida glabrata Knee One-stage exchange Infection cleared 4 yr
29 Brooks and Pupparo10 (1998) Candida parapsilosis Knee De´bridement Infection cleared 2 yr
30 Wada et al.36 1998 Candida parapsilosis Knee De´bridement Infection cleared 3 yr
31 Baumann et al.9 (2001) Aspergillus fumigatus Knee Resection arthroplasty Resection arthroplasty 5 yr
32 Ramamohan et al.32 (2001) (Candida albicans) Hip Resection arthroplasty Resection arthroplasty 2 yr
33 Yang et al.39 (2001) Candida parapsilosis Knee Two-stage exchange Infection cleared 4 yr
34 Merrer et al.28 (2001) Candida albicans Hip Antifungal therapy Infection cleared 11 mo
35 Acxikgo¨z et al.7 (2002) Candida glabrata Knee Resection arthroplasty Arthrodesis 30 wk
36 Marra et al.27 (2001) Candida albicans Hip Articulating spacer Resection arthroplasty N/A
37-40 Phelan et al.31 (2002) Candida albicans Hips (3) Two-stage exchange Infection cleared 4.3 yr
Candida albicans Knee (1) Two-stage exchange Infection cleared 4.3 yr
41 Wyman et al.38 (2002) Candida tropicalis Knee Two-stage exchange Infection cleared 3 yr
42 Cutrona et al.41 (2002) Rhodotorula minuta Hip Two-stage exchange Infection cleared N/A
43 Lerch et al.24 (2003) Candida albicans Knee Resection arthroplasty Arthrodesis 2 yr
44 Langer et al.22 (2003) Aspergillus niger Knee Antifungal therapy Infection cleared 1 yr
45 Lazzarini et al.23 (2004) Candida albicans Hip Resection arthroplasty Resection arthroplasty 4 yr
46 Gaston and Ogden16 (2004) Candida glabrata Knee Resection arthroplasty Amputation 6 mo
*N/A = not available.
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showed a sensitivity to amphotericin with average minimal
inhibitory concentration values ranging from 0.5 to 1 mg/mL.
Two patients experienced side effects of amphotericin treat-
ment, namely, an elevated serum creatinine level in one patient
and rigors and nausea in another. Following reimplantation,
oral fluconazole was routinely prescribed for six months with
regular monitoring of liver function tests.
Discussion
Periprosthetic infection caused by fungal pathogens is rare.Little is known about the prevalence of those infections,
the accuracy of the currently used diagnostic modalities, or the
most effective treatment protocol. We found a total of forty-six
cases of reported fungal periprosthetic joint infection7-40 after
searching the English-language literature from 1979 to 2008
(Table I). Most of those infections were caused by Candida
species. Candida albicans was the causative organism in twenty-
one of forty-six cases11,13,14,19,20,23-25,27,28,31,34. Candida parapsilosis
was the second leading cause of fungal periprosthetic joint
infection and was isolated in eleven cases10,12,15,18,26,30,35-37,39,40,
Candida glabrata was isolated from five cases7,16,17,29,32,33, and
Candida tropicalis from five cases13,17,21,38. Rhodotorula minuta
was reported as the cause of a periprosthetic infection in one
case report41. In the remaining three reported cases, Aspergillus
species (Aspergillus fumigatus and Aspergillus niger) was the
causative pathogen8,9,22. A similar organism profile was noted in
the present report (Fig. 3).
It seems that the most important virulence factor for
fungi, especially Candida albicans, in the pathogenesis of per-
iprosthetic infection is biofilm formation. Biofilm confers re-
sistance to antifungal agents. It has been shown that Candida
albicans produces larger and more complex biofilms than other
Candida species do42,43. Host factors appear to play an im-
portant role in development of invasive fungal infections. At
least one underlying chronic medical condition was identified
in twenty-seven of the thirty-one patients in this series.
However, among the previously reported cases of fungal
prosthetic infections, roughly half of the patients had no ob-
vious immunity-impairing risk factors39. Other important
predisposing factors include multiple revision surgeries and
complex reconstructions, the effect of which could be ex-
plained in part by the role of prolonged hospitalizations, which
have also been identified as a risk factor for the development of
candidemia6.
The diagnosis of a fungal periprosthetic joint infection
can be quite challenging. The mere demonstration of fungi in
tissue or fluid samples obtained with aspiration of a prosthetic
joint can be indicative of a true infection or fungal coloniza-
tion. The dilemma is more pronounced when the culture
demonstrates fungal organisms in association with an estab-
lished bacterial infection. In all of our patients, serological
values and joint-fluid cell counts could not distinguish a fungal
infection from a bacterial infection with fungal contamination.
The identification of fungal pathogens in synovial fluid or
purulent secretions on Gram stains is rare. Examination of
tissue samples should be done with use of special stains and
cultures. The cultures should not be considered negative for
growth until four weeks after incubation. In one study7, fungi
were not detected in any tissue sample until scrapings from the
surface of the explanted prosthesis were examined. In other
studies24,30, the diagnosis of candidal prosthetic infection has
been confirmed with direct histologic evidence of fungi in
retrieved osseous specimens. Several investigators10,32,33,36 have
stressed the importance of repeating fluid cultures and ob-
taining multiple positive tissue cultures before a diagnosis of
fungal periprosthetic joint infection is made.
This study showed that irrigation and de´bridement
alone, as was undertaken for a subset of the patients, failed
to control the infection. Wada et al.36 successfully treated
a Candida parapsilosis infection of the knee with de´bridement
and a regimen of oral fluconazole sodium (400 mg/day) for six
months. Only a few other reports10,15,34 have shown successful
treatment of fungal periprosthetic joint infection with de´-
bridement alone, which suggests that resection arthroplasty,
Fig. 3
Number of fungal periprosthetic infections reported so far according to our literature search.
C. = Candida.
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in accordance with the guidelines of the Infectious Diseases
Society of America (IDSA)44, should be undertaken when
a fungal infection is confirmed. Additionally, de´bridement
with retention of the prosthesis is unlikely to result in reso-
lution of the fungal infection, as fungal infection almost always
presents as a chronic infection in an immunocompromised
host, both of which are recognized causes of failure of
de´bridement alone45,46. Two-stage exchange arthroplasty failed
to control the infection in ten of nineteen patients in this
cohort. Phelan et al.31 reported a recurrence rate of 20% after
two-stage reimplantation for the treatment of candidal peri-
prosthetic joint infection. When the results of this series are
incorporated and viewed as a whole, it seems possible that the
risk of relapse following delayed reimplantation arthroplasty
for treatment of a fungal periprosthetic joint infection could be
as high as 25%. One-stage exchange arthroplasty for fungal
periprosthetic infection has been successful in only one re-
ported case33.
To date, there is no general consensus regarding the type
and dose of antifungal agents that can be used locally, mixed
with cement, or administered systemically to treat this chal-
lenging condition. Because of the fact that it is heat stable,
broad spectrum, and available in sterile powder form, am-
photericin B appears to be an ideal agent to be mixed with
cement; however, a previous study showed no elution of am-
photericin B from Simplex bone cement (Stryker Orthopae-
dics, Mahwah, New Jersey) after one week in vitro47. Another
study showed undetectable serum concentrations of ampho-
tericin B at fifty hours in vivo when mixed with Palacos bone
cement (Biomet, Warsaw, Indiana)27. This means that an ef-
fective method of local delivery of an antifungal agent remains
undetermined.
The drugs of choice for systemic administration in pa-
tients who are infected with Candida species are amphotericin
B and fluconazole44. Drug therapy alone will only suppress
clinical symptoms of infection at the expense of potential toxic
side effects. Treatment with antifungal agents has been re-
ported to be successful without surgical intervention in two
previous reports12,28, but resistance of Candida species to azole
drugs has been reported33. In the current series, resistance to
fluconazole was noted among Candida glabrata infections.
Thus, selecting the appropriate antifungal treatment requires
antifungal susceptibility testing and a multiteam approach
involving infectious disease specialists, clinical pharmacolo-
gists, and the treating orthopaedic surgeon. Although the exact
duration of therapy is not agreed upon, it seems that, on the
basis of previous reports, a minimum of one year is necessary
to ensure resolution of the infection12,15,35. The IDSA guidelines
for the duration of treatment with antifungal agents in the
treatment of native joint arthritis are six to twelve months
(Grade-BIII recommendation)44,48.
In summary, the findings of this first large-scale multi-
center study on prosthetic joint infections caused by fungal
pathogens support the notion that proper tissue de´bridement
and removal of the arthroplasty components may be the ap-
propriate surgical treatment for the majority of patients.
De´bridement and retention of components has a limited role
and should be reserved for the healthy host with excellent soft
tissues and a truly acute infection. Two-stage exchange ar-
throplasty is the treatment of choice. It is important to ensure
that antibacterial drugs are also added to the cement spacer to
prevent superinfection or to treat coexistent bacterial patho-
gens. The appropriate choice of antifungal agent for addition
to the cement spacer remains controversial. At present, the
only available agent is amphotericin. The determination of the
appropriate dose of this drug depends on the type of fungal
infection, the sensitivity of the pathogen to this drug, and the
preexisting comorbidities of the host. Systemic antifungal
therapy should then be initiated on the basis of the results of
fungal susceptibility testing, and this therapy should be con-
tinued until resolution of the infection can be established on
the basis of clinical and serological evaluation. Prior to re-
implantation, repeat joint aspirations should be performed in
all patients. According to the guidelines issued by the IDSA48,
antifungal drugs should be administered for a total duration of
six to twelve months. All efforts should be made to optimize
the host prior to reimplantation. The nutritional status of the
host should be evaluated and, when necessary, corrected. Re-
implantation should therefore be deferred until immunity-
impairing risk factors have been reversed or minimized. n
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